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Background: Guidelines recommend the use of ASA, clopidogrel, beta-blockers, ACE inhibitors, and anti-lipid therapies for secondary prevention 
post-acute myocardial infarction (AMI). However, there is limited data with respect to patient adherence to these recommendations at 12 months 
post-AMI.
Methods: We performed a secondary analysis of a double-blind, placebo-controlled trial of bupropion for smoking cessation in AMI patients. Data 
on medication use at baseline and 12 months post-AMI were available for 292 participants.
Results: Participants were predominantly male (85%) with a mean age of 54 (SD 10). Twenty percent had a prior MI and 68% presented with a ST-
segment elevation MI. A third of patients were from less developed countries (India, Iran, Pakistan and Tunisia). Differences in medication use were 
attributable to lower rates of percutaneous coronary intervention in less developed (12%) versus developed countries (72%). This trend was primarily 
evident in lower clopidogrel and higher nitrate use (see Figure). Use of most medications (e.g. beta-blockers, ACE inhibitors, anti-lipids) had declined 
by 12 months, particularly in less developed countries. While nearly all participants used ASA at baseline (98%), use declined to 93% in developed 
and 77% in less developed countries by 12 months.
Conclusions: While adherence to evidence-based medications at 12 months post-AMI was high, strategies are needed to narrow gaps in 
adherence between patients in developed and less developed countries.
 
